Quest Products, LLLC. (Quest) today announced its acquisition of Summit Pharmaceuticals / Alliance Labs. Quest is a portfolio company of Promus Equity Partners (Promus).
With this merger, Quest will add the Enemeez® and DocuSol® brands of bowel care products, to its’ portfolio of self-care products including OraCoat® for Dry Mouth, Clinere® for Ear Cleaning, Alocane® for Emergency Burns, SUNBURNT® for after-sun skin recovery and ProVent® for various First Aid Skin Conditions.
Enemeez® DocuSol® have been a preferred and trusted formula assisting patients improve their bowel care needs for more than 15 years. The formulation utilized in these products was developed for patients who experience autonomic dysreflexia, hemorrhoids, fissures, or painful bowel movements.
“We are proud to add both the Enemeez® and DocuSol® brands to our portfolio of category-leading brands” Mike Brennan President & CEO of Quest commented. “We are excited to partner with the Summit Pharmaceuticals Team and to expand both the Medical and OTC businesses domestically and internationally.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Amy Powers, CEO and founder of Summit Pharmaceuticals/Alliance Labs, “I am very proud of what the team has accomplished to build both the Enemeez® and DocuSol® brands so patients and consumers can maximize their lives. We have built a great company, we have helped improve lives, and I’m excited to see the Quest Team take it to new levels of success in the years to come.”
Bentley Associates, LP advised Summit Pharmaceuticals / Alliance Labs in the transaction, while Norton Rose Fulbright provided legal representation. Reinhart Boerner Van Deuren provided legal counsel to Quest.
PGIM, Inc. provided a senior credit facility. Terms of the investment were not disclosed.
Source: Biospace
